GlassScriptPhysician profile
Ashish K Basu
NPI 1407826233
$5,825.71
in general payments reported to CMS, 2019-2025
30 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $489 · 2021: $522 · 2022: $600 · 2023: $1,085 · 2024: $1,182 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,232.95 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $725.50 | 2019-2024 | Xarelto |
| Pfizer INC. | $534.43 | 2019-2025 | |
| Amgen INC. | $450.50 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $309.93 | 2019-2024 | |
| Ge Healthcare | $296.29 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $273.97 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $262.83 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $262.82 | 2022-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $217.98 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $199.66 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.06 | 2019-2025 | Jardiance |
| Abbott Laboratories | $144.44 | 2021-2025 | Jot Dx, Accent, Aveir |
| Astrazeneca Pharmaceuticals LP | $138.10 | 2020-2024 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $73.20 | 2024 | Amvuttra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $69.44 | 2024 | |
| Astellas Pharma US INC | $63.65 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $63.31 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $56.51 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Esperion Therapeutics, INC. | $49.87 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $37.66 | 2024 | Arcalyst |
| Beta Bionics, INC. | $33.56 | 2024 | Ilet Bionic Pancreas |
| Impulse Dynamics (USA) INC. | $26.68 | 2023 | Optimizer |
| Cvrx, INC. | $22.61 | 2025 | Barostim Neo System |
| Lantheus Medical Imaging, INC. | $22.51 | 2019 | |
| Inspire Medical Systems, INC. | $20.92 | 2024 | Inspire |
| Bridgebio Pharma, INC. | $20.68 | 2025 | Attruby |
| Medtronic, INC. | $15.74 | 2024 | Telescope |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2019 | |
| Irhythm Technologies, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Basu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.